Kyverna Therapeutics, Inc. cotiza a 5.82 USD y tiene una capitalización bursátil de $360M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. T…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.63 | $-0.80 |
| Estimado | $-0.74 | $-0.68 | $-0.68 | $-0.86 |
| Sorpresa | — | — | +7.4% | +7.0% |
| Métrica | KYTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -69.5% | -40.4% | -29.1% |
| ROA | -54.9% | -32.0% | -22.9% |
| Current Ratio | 7.75 | 2.84 | +4.91 |
| Debt / Equity | — | 0.28 | — |